Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 238 adjuvant nivolumab versus ipilimumab in resected high-risk melanoma
NL-OMON55473Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of nivolumab and ipilimumab, sponsored by Bristol Myers Squibb. Started May 2015; status: completed.
02
Drugs
nivolumabipilimumab
Beyond the preview
Go deeper on NL-OMON55473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55473.